<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03440541</url>
  </required_header>
  <id_info>
    <org_study_id>4102017NCRRT</org_study_id>
    <nct_id>NCT03440541</nct_id>
  </id_info>
  <brief_title>Uses of Gamma Irradiated Amniotic Membrane as an Alternative Method in Psoriasis Treatment</brief_title>
  <official_title>Uses of Gamma Irradiated Amniotic Membrane as an Alternative Method in Psoriasis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Egyptian Atomic Energy Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Egyptian Atomic Energy Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using of human amniotic membrane extra-cellular matrix as a topical treatment for improving
      Psoriasis Area and Severity Index (PASI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human amniotic membrane extra-cellular matrix was purchased from National center for
      radiation research and technology, Egypt, under commercial name REGE pro gel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 4, 2015</start_date>
  <completion_date type="Actual">April 8, 2016</completion_date>
  <primary_completion_date type="Actual">February 13, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scaling size decrement</measure>
    <time_frame>2 weeks</time_frame>
    <description>REGE pro gel decreased scaling size in patients with sever scales to moderate scale within two weeks, scaling size decrement from moderate to mild within two weeks, and from mild to complete curing within two weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histopathological improvement</measure>
    <time_frame>6 weeks</time_frame>
    <description>Two biopsies were taken from each patient before and at the end of the treatment. It was noted that all histological signs as munro's microabscess and the elongation of rete ridges were absent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erythema disappearing</measure>
    <time_frame>4-6 weeks</time_frame>
    <description>REGE pro gel gradually decreased erythema in patients within 4-6 weeks, these data were collected from applied patients by questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who received patches of REGE pro on psoriasis lesion weekly for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>REGE pro</intervention_name>
    <description>REGE pro is a patch of human amniotic membrane sterilized by gamma radiation</description>
    <arm_group_label>treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients have psoriasis lesion

        Exclusion Criteria:

          -  must stop other line of treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nashwa K Radwan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY</affiliation>
  </overall_official>
  <reference>
    <citation>Alikarami F, Yari F, Amirizadeh N, Nikougoftar M, Jalili MA. The Immunosuppressive Activity of Amniotic Membrane Mesenchymal Stem Cells on T Lymphocytes. Avicenna J Med Biotechnol. 2015 Jul-Sep;7(3):90-6.</citation>
    <PMID>26306147</PMID>
  </reference>
  <reference>
    <citation>Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. J Invest Dermatol. 1995 Jul;105(1 Suppl):89S-94S. Review.</citation>
    <PMID>7616005</PMID>
  </reference>
  <reference>
    <citation>Chen CP, Chen YY, Huang JP, Wu YH. The effect of conditioned medium derived from human placental multipotent mesenchymal stromal cells on neutrophils: possible implications for placental infection. Mol Hum Reprod. 2014 Nov;20(11):1117-25. doi: 10.1093/molehr/gau062. Epub 2014 Aug 19.</citation>
    <PMID>25140001</PMID>
  </reference>
  <reference>
    <citation>Gisondi P, Di Mercurio M, Idolazzi L, Girolomoni G. Concept of Remission in Chronic Plaque Psoriasis. J Rheumatol Suppl. 2015 Nov;93:57-60. doi: 10.3899/jrheum.150638. Review.</citation>
    <PMID>26523059</PMID>
  </reference>
  <reference>
    <citation>John T, Foulks GN, John ME, Cheng K, Hu D. Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. Ophthalmology. 2002 Feb;109(2):351-60.</citation>
    <PMID>11825823</PMID>
  </reference>
  <reference>
    <citation>Kronsteiner B, Wolbank S, Peterbauer A, Hackl C, Redl H, van Griensven M, Gabriel C. Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells. Stem Cells Dev. 2011 Dec;20(12):2115-26. doi: 10.1089/scd.2011.0031. Epub 2011 Apr 19.</citation>
    <PMID>21381973</PMID>
  </reference>
  <reference>
    <citation>Li J, Koike-Soko C, Sugimoto J, Yoshida T, Okabe M, Nikaido T. Human Amnion-Derived Stem Cells Have Immunosuppressive Properties on NK Cells and Monocytes. Cell Transplant. 2015;24(10):2065-76. doi: 10.3727/096368914X685230. Epub 2014 Oct 20.</citation>
    <PMID>25333453</PMID>
  </reference>
  <reference>
    <citation>Ma L, Zhou Z, Zhang D, Yang S, Wang J, Xue F, Yang Y, Yang R. Immunosuppressive function of mesenchymal stem cells from human umbilical cord matrix in immune thrombocytopenia patients. Thromb Haemost. 2012 May;107(5):937-50. doi: 10.1160/TH11-08-0596. Epub 2012 Mar 8.</citation>
    <PMID>22398715</PMID>
  </reference>
  <reference>
    <citation>Magatti M, Caruso M, De Munari S, Vertua E, De D, Manuelpillai U, Parolini O. Human Amniotic Membrane-Derived Mesenchymal and Epithelial Cells Exert Different Effects on Monocyte-Derived Dendritic Cell Differentiation and Function. Cell Transplant. 2015;24(9):1733-52. doi: 10.3727/096368914X684033. Epub 2014 Aug 19.</citation>
    <PMID>25259480</PMID>
  </reference>
  <reference>
    <citation>Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016 Jan;38(1):11-27. doi: 10.1007/s00281-015-0539-8. Epub 2015 Nov 16. Review.</citation>
    <PMID>26573299</PMID>
  </reference>
  <reference>
    <citation>McDonald CA, Payne NL, Sun G, Moussa L, Siatskas C, Lim R, Wallace EM, Jenkin G, Bernard CC. Immunosuppressive potential of human amnion epithelial cells in the treatment of experimental autoimmune encephalomyelitis. J Neuroinflammation. 2015 Jun 3;12:112. doi: 10.1186/s12974-015-0322-8.</citation>
    <PMID>26036872</PMID>
  </reference>
  <reference>
    <citation>Pianta S, Bonassi Signoroni P, Muradore I, Rodrigues MF, Rossi D, Silini A, Parolini O. Amniotic membrane mesenchymal cells-derived factors skew T cell polarization toward Treg and downregulate Th1 and Th17 cells subsets. Stem Cell Rev. 2015 Jun;11(3):394-407. doi: 10.1007/s12015-014-9558-4.</citation>
    <PMID>25348066</PMID>
  </reference>
  <reference>
    <citation>Redondo P, Giménez de Azcarate A, Marqués L, García-Guzman M, Andreu E, Prósper F. Amniotic membrane as a scaffold for melanocyte transplantation in patients with stable vitiligo. Dermatol Res Pract. 2011;2011:532139. doi: 10.1155/2011/532139. Epub 2011 Aug 18.</citation>
    <PMID>21869882</PMID>
  </reference>
  <reference>
    <citation>Yamahara K, Harada K, Ohshima M, Ishikane S, Ohnishi S, Tsuda H, Otani K, Taguchi A, Soma T, Ogawa H, Katsuragi S, Yoshimatsu J, Harada-Shiba M, Kangawa K, Ikeda T. Comparison of angiogenic, cytoprotective, and immunosuppressive properties of human amnion- and chorion-derived mesenchymal stem cells. PLoS One. 2014 Feb 14;9(2):e88319. doi: 10.1371/journal.pone.0088319. eCollection 2014.</citation>
    <PMID>24551087</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2017</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2018</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Egyptian Atomic Energy Authority</investigator_affiliation>
    <investigator_full_name>Nashwa Radwan</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Amniotic membrane</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

